[go: up one dir, main page]

SG11201707989PA - Compositions containing ibrutinib - Google Patents

Compositions containing ibrutinib

Info

Publication number
SG11201707989PA
SG11201707989PA SG11201707989PA SG11201707989PA SG11201707989PA SG 11201707989P A SG11201707989P A SG 11201707989PA SG 11201707989P A SG11201707989P A SG 11201707989PA SG 11201707989P A SG11201707989P A SG 11201707989PA SG 11201707989P A SG11201707989P A SG 11201707989PA
Authority
SG
Singapore
Prior art keywords
compositions containing
containing ibrutinib
ibrutinib
compositions
Prior art date
Application number
SG11201707989PA
Inventor
Dilip Gole
Manish Kumar Gupta
Kaustubh Tambwekar
Binuraj Krishnan Nair
Maristella Bernini
Sabine Inghelbrecht
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806788&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201707989P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SG11201707989PA publication Critical patent/SG11201707989PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16Inorganic salts, minerals or trace elements
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/10Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic in stationary drums or troughs, provided with kneading or mixing appliances
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/22Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by pressing in moulds or between rollers
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833Encapsulating processes; Filling of capsules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201707989PA 2015-04-06 2016-04-06 Compositions containing ibrutinib SG11201707989PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562143659P 2015-04-06 2015-04-06
PCT/US2016/026134 WO2016164404A1 (en) 2015-04-06 2016-04-06 Compositions containing ibrutinib

Publications (1)

Publication Number Publication Date
SG11201707989PA true SG11201707989PA (en) 2017-10-30

Family

ID=55806788

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201707989PA SG11201707989PA (en) 2015-04-06 2016-04-06 Compositions containing ibrutinib
SG10202103458QA SG10202103458QA (en) 2015-04-06 2016-04-06 Compositions containing ibrutinib

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202103458QA SG10202103458QA (en) 2015-04-06 2016-04-06 Compositions containing ibrutinib

Country Status (29)

Country Link
US (5) US20160287594A1 (en)
EP (3) EP3280446A1 (en)
JP (3) JP2018513852A (en)
KR (2) KR20240013859A (en)
CN (2) CN113546054A (en)
AU (3) AU2016246669B2 (en)
CA (1) CA2981601A1 (en)
CL (1) CL2017002512A1 (en)
DK (1) DK3892302T3 (en)
EA (1) EA033992B1 (en)
ES (1) ES2964472T3 (en)
FI (1) FI3892302T3 (en)
HK (1) HK1250925A1 (en)
HR (1) HRP20231207T1 (en)
HU (1) HUE063751T2 (en)
IL (2) IL295941A (en)
LT (1) LT3892302T (en)
MA (2) MA54411B1 (en)
MD (1) MD3892302T2 (en)
MX (2) MX2017012822A (en)
PH (1) PH12017501811A1 (en)
PL (1) PL3892302T3 (en)
PT (1) PT3892302T (en)
RS (1) RS64653B1 (en)
SG (2) SG11201707989PA (en)
SI (1) SI3892302T1 (en)
SM (1) SMT202300422T1 (en)
UA (1) UA125681C2 (en)
WO (1) WO2016164404A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2875986C (en) 2012-06-04 2020-06-09 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor
KR20170033358A (en) 2014-08-07 2017-03-24 파마싸이클릭스 엘엘씨 Novel formulations of a bruton's tyrosine kinase inhibitor
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of proton tyrosine kinase inhibitor
SI3892302T1 (en) 2015-04-06 2023-11-30 Janssen Pharmaceutica Nv Compositions containing ibrutinib
WO2018065504A1 (en) 2016-10-06 2018-04-12 Janssen Pharmaceutica Nv Processes and intermediates for preparing a btk inhibitor
US11918684B2 (en) 2017-03-13 2024-03-05 Liqmeds Worldwide Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
CN108653231A (en) * 2017-04-01 2018-10-16 北京赛林泰医药技术有限公司 Composition and preparation method thereof containing bruton's tyrosine kinase inhibitor
CN107014943B (en) * 2017-06-07 2018-08-21 福建省微生物研究所 A kind of detection method of ibrutinib enantiomer
WO2019038584A1 (en) 2017-08-19 2019-02-28 Ftf Pharma Private Limited An oral pharmaceutical composition comprising zonisamide and process of preparation thereof
EP3687505A1 (en) 2017-09-26 2020-08-05 Tesaro Inc. Niraparib formulations
CA3089537A1 (en) 2018-01-20 2019-07-25 Natco Pharma Limited Pharmaceutical compositions comprising ibrutinib
KR20190122561A (en) * 2018-04-21 2019-10-30 류형준 Lymphatic circulation promotor
CA3100146A1 (en) 2018-06-15 2019-12-19 Janssen Pharmaceutica Nv Formulations/compositions comprising ibrutinib
CN112566625A (en) * 2018-08-18 2021-03-26 夫特弗制药私人有限公司 Oral dosage chemotherapeutic drug suspensions
GB2591396B (en) * 2018-08-18 2023-06-07 Ftf Pharma Private Ltd Pharmaceutical suspension for oral dosage
KR102198502B1 (en) * 2018-09-16 2021-01-05 류형준 Food composition for lymphokinesis improvement in human organism
US20200171034A1 (en) * 2018-11-30 2020-06-04 Janssen Biotech, Inc. Methods Of Treating Follicular Lymphoma
US10688050B1 (en) 2018-12-21 2020-06-23 Synthon B.V. Pharmaceutical composition comprising ibrutinib
KR102251435B1 (en) * 2020-11-09 2021-05-11 류형준 Food composition for treating or alleviating edema by promotion of lymphokinesis
MA63498A1 (en) * 2021-06-10 2024-07-31 Hikma Pharmaceuticals Usa Inc. ORAL DOSAGE FORMS OF IBRUTINIB
US11433072B1 (en) * 2021-06-10 2022-09-06 Hikma Pharmaceuticals USA, Inc. Oral dosage forms of ibrutinib
CN117064862A (en) * 2023-04-10 2023-11-17 山东新时代药业有限公司 Ibutenib enteric-coated tablet and preparation method thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK607188A (en) 1987-11-02 1989-06-22 Merck & Co Inc TABLE CONTAINING A PHTHALAZINE ACETIC ACID COMPOUND
US5994348A (en) 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
DE10201304A1 (en) 2002-01-15 2003-07-31 Infineon Technologies Ag Non-volatile semiconductor memory cell and associated manufacturing process
DE602006013114D1 (en) * 2005-04-28 2010-05-06 Wyeth Corp MICRONIZED TANAPROGET AND COMPOSITIONS THEREWITH
SI2526934T1 (en) 2006-09-22 2016-04-29 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
US20120101113A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US8003309B2 (en) 2008-01-16 2011-08-23 International Business Machines Corporation Photoresist compositions and methods of use in high index immersion lithography
EA031737B1 (en) 2010-06-03 2019-02-28 Фармасайкликс, Инк. USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (Btk) FOR TREATING LEUKEMIA AND LYMPHOMA
US20140303191A1 (en) * 2011-10-19 2014-10-09 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
CA2875986C (en) 2012-06-04 2020-06-09 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor
US20150140085A1 (en) 2012-06-29 2015-05-21 Principia Biopharma Inc. Formulations comprising ibrutinib
EP3827863B1 (en) 2013-03-14 2023-06-07 Fisher & Paykel Healthcare Limited Catheter mount with suction port
TWI609012B (en) 2013-04-28 2017-12-21 廣東東陽光藥業有限公司 Aminoquinazoline derivatives and their salts and methods of use thereof
CN105452394A (en) * 2013-08-12 2016-03-30 横滨橡胶株式会社 Primer composition
WO2015023703A1 (en) * 2013-08-12 2015-02-19 Pharmacyclics, Inc. Methods for the treatment of her2 amplified cancer
WO2015071432A1 (en) * 2013-11-14 2015-05-21 Sandoz Ag Pharmaceutical compositions of ibrutinib
WO2015140709A1 (en) 2014-03-19 2015-09-24 Novartis Ag Solid pharmaceutical dosage forms
CA2955744A1 (en) 2014-08-01 2016-02-04 Pharmacyclics Llc Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor
KR20170033358A (en) 2014-08-07 2017-03-24 파마싸이클릭스 엘엘씨 Novel formulations of a bruton's tyrosine kinase inhibitor
CN104523695A (en) * 2014-11-12 2015-04-22 广东东阳光药业有限公司 A kind of pharmaceutical composition for treating hyperproliferative diseases
CN104407067B (en) * 2014-11-17 2016-01-20 广东东阳光药业有限公司 The detection method of Buddhist nun and isomeride thereof is replaced according to Shandong
IL315294A (en) * 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of proton tyrosine kinase inhibitor
SI3892302T1 (en) 2015-04-06 2023-11-30 Janssen Pharmaceutica Nv Compositions containing ibrutinib
AU2017268839A1 (en) 2016-05-27 2018-11-29 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat B-cell proliferative disorders

Also Published As

Publication number Publication date
FI3892302T3 (en) 2023-11-03
US20160287594A1 (en) 2016-10-06
US12364698B2 (en) 2025-07-22
IL254695B (en) 2022-10-01
US20230263804A1 (en) 2023-08-24
CN113546054A (en) 2021-10-26
WO2016164404A1 (en) 2016-10-13
KR102632745B1 (en) 2024-02-01
US20200171036A1 (en) 2020-06-04
MA41901A (en) 2021-04-14
HRP20231207T1 (en) 2024-01-19
AU2021250925B2 (en) 2023-11-16
MX2017012822A (en) 2018-06-13
EP3892302B1 (en) 2023-09-06
MA54411B1 (en) 2023-11-30
JP2022031690A (en) 2022-02-22
IL254695A0 (en) 2017-11-30
IL295941A (en) 2022-10-01
DK3892302T3 (en) 2023-11-13
KR20240013859A (en) 2024-01-30
LT3892302T (en) 2023-11-10
MX2021015250A (en) 2022-01-24
IL254695B2 (en) 2023-02-01
HUE063751T2 (en) 2024-01-28
EP3892302A1 (en) 2021-10-13
CA2981601A1 (en) 2016-10-13
MA54411A (en) 2021-10-13
AU2016246669A1 (en) 2017-10-12
KR20170134582A (en) 2017-12-06
US20220211713A1 (en) 2022-07-07
CL2017002512A1 (en) 2018-03-16
UA125681C2 (en) 2022-05-18
EP3280446A1 (en) 2018-02-14
JP2024026087A (en) 2024-02-28
US20170252344A1 (en) 2017-09-07
SMT202300422T1 (en) 2024-01-10
ES2964472T3 (en) 2024-04-08
EA201792224A1 (en) 2018-06-29
RS64653B1 (en) 2023-10-31
HK1250925A1 (en) 2019-01-18
AU2016246669B2 (en) 2021-07-15
AU2021250925A1 (en) 2021-11-11
AU2024200883A1 (en) 2024-02-29
EP4272835A2 (en) 2023-11-08
EP3892302B8 (en) 2023-10-18
EA033992B1 (en) 2019-12-17
PL3892302T3 (en) 2024-03-11
MD3892302T2 (en) 2024-03-31
PH12017501811A1 (en) 2018-04-23
PT3892302T (en) 2023-11-15
JP7438178B2 (en) 2024-02-26
SG10202103458QA (en) 2021-05-28
BR112017021325A2 (en) 2018-06-26
JP2018513852A (en) 2018-05-31
SI3892302T1 (en) 2023-11-30
EP4272835A3 (en) 2023-12-20
CN107530293A (en) 2018-01-02

Similar Documents

Publication Publication Date Title
IL254695A0 (en) Compositions containing ibrutinib
GB201512030D0 (en) Composition
GB201505527D0 (en) Composition
GB201601572D0 (en) NO containing compositions
GB201506827D0 (en) Composition
GB201506830D0 (en) Composition
GB201506825D0 (en) Composition
GB201515640D0 (en) Composition
GB201506829D0 (en) Composition
GB201504665D0 (en) Composition
GB201517546D0 (en) Composition
GB201518348D0 (en) Composition
GB201515639D0 (en) Composition
GB201514585D0 (en) Composition
GB201506828D0 (en) Composition
GB201505520D0 (en) Composition
GB201504307D0 (en) Composition
GB201511697D0 (en) Composition
GB201509044D0 (en) Composition
GB2536640B (en) Epilatory compositions
GB2536642B (en) Epilatory compositions
GB201515734D0 (en) Composition
GB201508722D0 (en) Composition
GB201506826D0 (en) Composition
GB201509641D0 (en) Composition